AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15692069
Drug: Lymphocytotoxic antibody
RxNorm normalized name: Lymphocytotoxic antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphocytotoxic antibody positivity
Trial: 7751898
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (RA) 45 mg/m2 orally twice per day for 14 days (Cycle 1)
Trial: 7751898
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (RA) 45 mg/m2 orally twice per day for 14 days plus ketoconazole 400 mg orally for one dose, then 200 mg orally three times per day for 14 days (Cycle 2)
Trial: 12496753
Drug: Ketoconazole administration
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole administration
Trial: 27125966
Drug: Hormone Manipulation
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Manipulation (HM; tamoxifen or LHRH agonists)
Trial: 27125966
Drug: Hormone Manipulation
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Manipulation (HM; tamoxifen or LHRH agonists) in ER+/unknown disease
Trial: 27125966
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment groups (FE50C-HM, FE50C+HM, FE75C-HM, FE75C+HM)
Trial: 22296781
Drug: Insulin (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (daily bedtime subcutaneous NPH insulin)
Trial: 22296781
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (oral hypoglycemic agents)
Trial: 17619859
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg rimonabant daily for 15 days
Trial: 17619859
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg rimonabant on day 15 after 14 days of placebo
Trial: 11573666
Drug: Intrathecal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal sufentanil 20 microg combined with morphine 200 microg
Trial: 11573666
Drug: Intrathecal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal sufentanil and morphine
Trial: 9757881
Drug: Systemic methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systemic methotrexate therapy
Trial: 28689102
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (1 dose of 1 g IV) once a month for 12 months
Trial: 25142619
Drug: Systemic Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic Family Therapy (alternate form)
Trial: 8943170
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) 1750 anti-Xa IU daily
Trial: 8943170
Drug: Standard unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard unfractionated heparin (UFH) 5000 IU twice a day
Trial: 1586105
Drug: Nal‐Glu (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nal‐Glu (GnRH antagonist) for 6 weeks
Trial: 1586105
Drug: Nal‐Glu plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nal‐Glu plus testosterone enanthate (100 mg/wk)
Trial: 4026044
Drug: Almitrine 50
RxNorm normalized name: almitrine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine 50 mg orally twice a day for 14 days
Trial: 26595549
Drug: SRT2104 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 50 mg daily
Trial: 26595549
Drug: SRT2104 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 500 mg daily
Trial: 26595549
Drug: SRT2104 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 (both doses)
Trial: 20368196
Drug: Intensified glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified glucose control based on insulin (I-group)
Trial: 20368196
Drug: Ongoing glucose-lowering
RxNorm normalized name: biguanide blood glucose lower drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ongoing glucose-lowering treatment (C-group)
Trial: 17990195
Drug: SHR-5 extract
RxNorm normalized name: Capsicum extract 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-5 extract (340 mg/day)
Trial: 17990195
Drug: SHR-5 extract
RxNorm normalized name: Capsicum extract 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-5 extract (680 mg/day)
Trial: 1922220
Drug: 283 mg
RxNorm normalized name: Docusol 283 MG per 5 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 283 mg of aspirin
Trial: 6420959
Drug: Ibuprofen (instead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (instead of steroids) with azathioprine and ATGAM for three months
Trial: 6420959
Drug: Azathioprine, high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine, high doses of prednisolone, and ATGAM for three months
Trial: 6420959
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (Ibuprofen)
Trial: 31006972
Drug: Nondrug ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondrug ultrasound (US) therapy
Trial: 25480588
Drug: Warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plus 75‐100 mg aspirin
Trial: 25480588
Drug: Warfarin only
RxNorm normalized name: Warfarin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin only
Trial: 21771042
Drug: Relaxation training
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation training programme (listening to a 13-minute relaxation programme daily)
Trial: 18185146
Drug: Lutein administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein administration
Trial: 15865225
Drug: PEG-IFN 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-IFN 1.5 microg/kg/week plus RBV 400 mg twice daily (arm A)
Trial: 9634050
Drug: Selenium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium treatment (200 microg daily)
Trial: 26581111
Drug: E6005 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6005 ointment (0.01% to 0.2%) in Study 001
Trial: 26581111
Drug: E6005 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6005 ointment (0.01% to 0.2%) in Study 101
Trial: 26581111
Drug: E6005 ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6005 ointment (0.01% to 0.2%) in both studies
Trial: 25332324
Drug: Daily snack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily snack made from green leafy vegetables, fruit, and milk (treatment group)
Trial: 17660154
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg albuterol
Trial: 17660154
Drug: 0.62 mg
RxNorm normalized name: karaya gum 0.62 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.62 mg albuterol
Trial: 9098301
Drug: Single intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraoperative application of 0.2 mg/ml mitomycin C for 3 minutes
Trial: 9098301
Drug: Single intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraoperative application of 0.4 mg/ml mitomycin C for 3 minutes
Trial: 9098301
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C eye drops 0.2 mg/ml three times daily for 7 days
Trial: 9098301
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C eye drops 0.4 mg/ml three times daily for 14 days
Trial: 2713212
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion at 0.07 mg kg‐1 min‐1
Trial: 2713212
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion at 0.03 mg kg‐1 min‐1
Trial: 2713212
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion at 0.005 mg kg‐1 min‐1
Trial: 946338
Drug: Pimozide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimozide (2 mg initially, then 1 mg/day)
Trial: 946338
Drug: Fusaric acid
RxNorm normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusaric acid (600 mg/day)
Trial: 30169244
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg three times daily until 32 weeks and 0 days' gestation or delivery
Trial: 24513094
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with timolol 0.5%
Trial: 24513094
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with brimonidine 0.2%
Trial: 22452789
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion after a 4-day high sodium diet (300 mmol sodium/day)
Trial: 22452789
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion after a 4-day low sodium diet (30 mmol sodium/day)
Trial: 22452789
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion during high sodium intake
Trial: 16080835
Drug: Bisoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (10 mg qd)
Trial: 16080835
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy (both bisoprolol and carvedilol)
Trial: 10426128
Drug: lonidamine (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lonidamine (450 mg daily p.o. until progression)
Trial: 10426128
Drug: vindesine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vindesine (3 mg/m2/daily i.v. weekly for 4 weeks and then every 2 weeks until progression)
Trial: 10426128
Drug: lonidamine +
RxNorm normalized name: lonidamine
DrugBank: Lonidamine (DB06266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lonidamine + vindesine (at the same dose and schedule)
Trial: 10426128
Drug: supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: supportive therapy only
Trial: 7493300
Drug: Recombinant interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant interferon-alpha 2a (IFN-alpha 2a) starting dose 6 MU, adjusted based on ALT response
Trial: 31753866
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise training (3 weekly sessions of 35 min moderate intensity walking/running and 25 min resistance training until delivery)
Trial: 2193560
Drug: Adenosine 12
RxNorm normalized name: adenosine 12 MG in 4 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine 12 mg
Trial: 27759898
Drug: Adenosine 18
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine 18 mg
Trial: 27759898
Drug: Adenosine 24
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine 24 mg
Trial: 27759898
Drug: Adenosine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (all doses)
Trial: 27759898
Drug: Adenosine (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (doses 18 mg and 24 mg)
Trial: 26423650
Drug: BMS-663068 400
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-663068 400 mg twice daily
Trial: 26423650
Drug: BMS-663068 800
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-663068 800 mg twice daily
Trial: 26423650
Drug: BMS-663068 600
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-663068 600 mg once daily
Trial: 26423650
Drug: BMS-663068 1200
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-663068 1200 mg once daily
Trial: 15126548
Drug: 0.9 mg
RxNorm normalized name: estradiol 0.9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg recombinant human TSH (rhTSH)
Trial: 11431171
Drug: t.i.d. tiagabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t.i.d. tiagabine (three times daily)
Trial: 11431171
Drug: b.i.d. tiagabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b.i.d. tiagabine (twice daily)
Trial: 1572037
Drug: Transient ST
RxNorm normalized name: ST-36
DrugBank: ST-36 (DB17275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transient ST segment abnormalities during daily activities
Trial: 29272068
Drug: Camelina Sativa
RxNorm normalized name: CAMELINA SATIVA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camelina Sativa Oil (10 g d‐1 ALA)
Trial: 15127083
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg lorazepam
Trial: 15512028
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcium and low-dose aspirin
Trial: 2195514
Drug: Piezoelectric inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piezoelectric inhalation device
Trial: 2195514
Drug: Metered-dose aerosols
RxNorm normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered-dose aerosols
Trial: 28629318
Drug: 0.05% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% chlorhexidine oral rinse solution
Trial: 28629318
Drug: Usual oral
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oral hygiene care (Control)
Trial: 28629318
Drug: Functional Oral
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Oral Intake Scale (FOIS)-level
Trial: 21487057
Drug: Betamethasone 12
RxNorm normalized name: Betamethasone 120 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone 12 mg intramuscularly for two consecutive days
Trial: 8050140
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with a combination of n‐3 (marine oil) and n‐6 (evening primrose oil) essential fatty acids
Trial: 2903876
Drug: Doxepin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (25 mg)
Trial: 2903876
Drug: Desipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (25 mg)
Trial: 19627681
Drug: Physiotherapy intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physiotherapy intervention including manual therapy, exercises, and psychological strategies, tailored individually with a maximum of six treatments over an 8-week period.
Trial: 28639229
Drug: MHAA4549A (400,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHAA4549A (400, 1200, or 3600 mg)
Trial: 28639229
Drug: Oseltamivir (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (75 mg twice daily from days 7 to 11)
Trial: 27632919
Drug: Prescription omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription omega-3 acid ethyl esters (O3AEE) 1 g/d
Trial: 17323547
Drug: Parenteral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral intake of 10% glucose solution with minerals (Group B)
Trial: 12673731
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and continuous-infusion doxorubicin (n = 26 patients)
Trial: 8679045
Drug: Total Intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Intravenous Anaesthesia (TIVA) with antiemetic prophylaxis (2.5 mg DHBP)
Trial: 8679045
Drug: Total Intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Intravenous Anaesthesia (TIVA) without antiemetic prophylaxis
Trial: 8679045
Drug: Balanced Anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced Anaesthesia with antiemetic prophylaxis (2.5 mg DHBP)
Trial: 8679045
Drug: Total Intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Intravenous Anaesthesia (TIVA) with DHBP
Trial: 6369557
Drug: mebendazole 500
RxNorm normalized name: mebendazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mebendazole 500 mg thrice daily for 21 days
Trial: 6369557
Drug: mebendazole 500
RxNorm normalized name: mebendazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mebendazole 500 mg thrice daily + levamisole hydrochloride 2.5 mg/kg weekly for 3 weeks
Trial: 31591650
Drug: 14 mg/d
RxNorm normalized name: nicotine 14 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg/d lactolycopene for 12 weeks
Trial: 31562797
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (1 mg/kg and 3 mg/kg respectively every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks)
Trial: 31562797
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg every 2 weeks) plus ipilimumab-matched placebo
Trial: 31562797
Drug: Ipilimumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (3 mg/kg every 3 weeks for four doses) plus nivolumab-matched placebo
Trial: 24383478
Drug: Erythromycin IV
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin IV 150 mg
Trial: 24383478
Drug: Morphine IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine IV 0.05 mg/kg BW
Trial: 11536417
Drug: Sleep therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep therapy programme (six-session group programme including stimulus control therapy, relaxation training, and other strategies)
Trial: 11536417
Drug: Sleep therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep therapy programme
Trial: 9604143
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg KW-4679 (single-dose trial)
Trial: 9604143
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg KW-4679 (multiple-dose trial)
Trial: 31413313
Drug: Tacrolimus and
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus and mTOR inhibitor (second-line treatment)
Trial: 31413313
Drug: Tacrolimus and
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus and mTOR inhibitor (third-line treatment)
Trial: 25135348
Drug: Intravenous glucose-insulin-potassium
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose-insulin-potassium (GIK) therapy
Trial: 24568002
Drug: Beech Brook
RxNorm normalized name: ALLERGENIC EXTRACT, BEECH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beech Brook Therapy Assessment Instrument
Trial: 17157592
Drug: Bimatoprost 0.03%
RxNorm normalized name: BIMATOPROST 0.03% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost 0.03% topical therapy with reduced drop-skin contact (eye 1)
Trial: 17157592
Drug: Bimatoprost 0.03%
RxNorm normalized name: BIMATOPROST 0.03% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost 0.03% topical therapy (fellow eye)
Trial: 14581436
Drug: MMC in
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC in combination with local microwave-induced hyperthermia
Trial: 10977126
Drug: Gelfoam disc
RxNorm normalized name: Sus scrofa intervertebral disc preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelfoam disc impregnated with 0.60 mg of tropicamide racemate and 1.7 mg of 1‐phenylephrine hydrochloride
Trial: 10977126
Drug: Topically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically administered drops (phenylephrine hydrochloride 2.5% solution and tropicamide 1% solution)
Trial: 16741368
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (once daily SLIT) with 10 days updosing (T1), 20 days maintenance treatment (T2), and 2 consecutive months on maintenance treatment (T3 and T4)
Trial: 16741368
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with placebo updosing (T1), placebo maintenance (T2), initiated active treatment at T3, and continued active treatment until the end of the study (T4)